Table 3 Most frequent adverse events over time in patients treated with first-line ibrutinib
Adverse events, n (%) | Ibrutinib n = 135a | |||||
|---|---|---|---|---|---|---|
0–1 year n = 135 | 1–2 years n = 123 | 2–3 years n = 111 | 3–4 years n = 100 | 4–5 years n = 89 | Totald,e n = 135 | |
Any gradeb | 133 (99) | 118 (96) | 104 (94) | 97 (97) | 87 (98) | 135 (100) |
Diarrhea | 57 (42) | 11 (9) | 13 (12) | 8 (8) | 8 (9) | 67 (50) |
Fatigue | 38 (28) | 27 (22) | 21 (19) | 19 (19) | 18 (20) | 48 (36) |
Cough | 26 (19) | 13 (11) | 12 (11) | 10 (10) | 11 (12) | 49 (36) |
Peripheral edema | 23 (17) | 17 (14) | 13 (12) | 12 (12) | 11 (12) | 37 (27) |
Anemia | 22 (16) | 12 (10) | 9 (8) | 9 (9) | 6 (7) | 35 (26) |
Nausea | 27 (20) | 9 (7) | 5 (5) | 3 (3) | 3 (3) | 35 (26) |
Pyrexia | 20 (15) | 8 (7) | 7 (6) | 6 (6) | 6 (7) | 36 (27) |
Arthralgia | 19 (14) | 13 (11) | 10 (9) | 6 (6) | 13 (15) | 35 (26) |
Upper respiratory tract infection | 17 (13) | 8 (7) | 10 (9) | 10 (10) | 7 (8) | 35 (26) |
Hypertension | 16 (12) | 12 (10) | 15 (14) | 16 (16) | 17 (19) | 31 (23) |
Constipation | 16 (12) | 14 (11) | 11 (10) | 6 (6) | 7 (8) | 28 (21) |
Vomiting | 16 (12) | 5 (4) | 7 (6) | 3 (3) | 1 (1) | 27 (20) |
Grade ≥3c | 78 (58) | 48 (39) | 30 (27) | 39 (39) | 32 (36) | 112 (83) |
Neutropenia | 11 (8) | 4 (3) | 1 (1) | 1 (1) | 0 (0) | 17 (13) |
Pneumonia | 7 (5) | 3 (2) | 3 (3) | 4 (4) | 2 (2) | 16 (12) |
Hypertension | 6 (4) | 2 (2) | 0 | 3 (3) | 4 (4) | 11 (8) |
Anemia | 8 (6) | 1 (1) | 1 (1) | 0 | 0 (0) | 10 (7) |
Hyponatremia | 3 (2) | 4 (3) | 0 | 0 | 1 (1) | 8 (6) |
Atrial fibrillation | 2 (1) | 0 | 4 (4) | 1 (1) | 0 (0) | 7 (5) |
Cataract | 1 (1) | 1 (1) | 1 (1) | 1 (1) | 3 (3) | 7 (5) |
Diarrhea | 5 (4) | 0 | 1 (1) | 0 | 0 (0) | 6 (4) |
